View Older Stories View More Recent Stories

Jan 28, 2022 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 11, 2022 08:11AM Esperion Therapeutics (ESPR) Reports Prelim Q4 Results, Provides CLEAR Outcomes Program Update
Jan 11, 2022 08:03AM Esperion Therapeutics (ESPR) Sees Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Million
Jan 11, 2022 08:00AM Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
Jan 11, 2022 08:00AM Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
Jan 6, 2022 08:00AM Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
Jan 6, 2022 08:00AM Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
Jan 4, 2022 08:00AM Esperion Appoints Benjamin O. Looker as General Counsel
Jan 4, 2022 08:00AM Esperion Appoints Benjamin O. Looker as General Counsel
Dec 7, 2021 04:05PM Esperion Announces Closing of $225 Million Public Offering
Dec 3, 2021 05:23AM Esperion Therapeutics (ESPR) Prices 32.14M Share Offering at $7/sh
Dec 2, 2021 11:40PM Esperion Announces Pricing of $225 Million Public Offering
Dec 2, 2021 11:40PM Esperion Announces Pricing of $225 Million Public Offering
Dec 2, 2021 05:00PM Esperion Therapeutics (ESPR) Announces Proposed Public Offering, Size not Disclosed
Dec 2, 2021 05:00PM Esperion Announces Proposed Public Offering
Nov 12, 2021 07:10AM Esperion Therapeutics (ESPR) Presents Important New Science Highlighting Potential Benefits of NEXLETOL Tablets at AHA
Nov 12, 2021 07:00AM Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
Nov 12, 2021 07:00AM Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
Nov 2, 2021 07:00AM Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
Nov 2, 2021 07:00AM Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update
Nov 1, 2021 04:01PM Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
Nov 1, 2021 04:01PM Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
Nov 1, 2021 07:01AM Esperion Therapeutics (ESPR) Appoints Seth H.Z. Fischer to its Board
Nov 1, 2021 07:00AM Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
Nov 1, 2021 07:00AM Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors
Oct 27, 2021 04:01PM Esperion to Participate in Upcoming Virtual Investor Conference
Oct 27, 2021 04:01PM Esperion to Participate in Upcoming Virtual Investor Conference
Oct 25, 2021 07:00AM ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock
Oct 25, 2021 07:00AM ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock
Oct 18, 2021 07:05AM Esperion Therapeutics (ESPR) Announces Plan for Transformative Long-Term Growth, Updates Outlook
Oct 18, 2021 07:00AM ESPERION Announces Plan for Transformative Long-Term Growth
Oct 18, 2021 07:00AM ESPERION Announces Plan for Transformative Long-Term Growth
Oct 12, 2021 08:00AM Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
Oct 12, 2021 08:00AM Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
Sep 7, 2021 04:01PM ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
Sep 7, 2021 04:01PM ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
Aug 26, 2021 08:00AM Esperion to Participate in Upcoming Virtual Investor Conference
Aug 26, 2021 08:00AM Esperion to Participate in Upcoming Virtual Investor Conference
Aug 3, 2021 07:00AM ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
Aug 3, 2021 07:00AM ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update
Jul 27, 2021 08:00AM Esperion to Participate in Upcoming Virtual Investor Conference
Jul 27, 2021 08:00AM Esperion to Participate in Upcoming Virtual Investor Conference
Jul 13, 2021 08:00AM Esperion to Report Second Quarter 2021 Financial Results August 3, 2021
Jul 13, 2021 08:00AM Esperion to Report Second Quarter 2021 Financial Results August 3, 2021
Jul 1, 2021 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 1, 2021 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 28, 2021 07:59AM ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
Jun 28, 2021 07:59AM ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
May 24, 2021 08:00AM Esperion to Participate in Two Upcoming Virtual Investor Conferences
May 24, 2021 08:00AM Esperion to Participate in Two Upcoming Virtual Investor Conferences
View More Recent Stories View Older Stories